Navigation Links
High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
Date:12/10/2013

BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the high cost per patient per year of biologics and novel oral therapies for the treatment of rheumatoid arthritis (RA) and psoriasis often results in reimbursement hurdles that limit patients' ability to access these therapies. Among RA patients in the United States who are eligible but do not receive a biologic/novel oral therapy (approximately 10 percent of disease-modifying antirheumatic [DMARD]-treated RA patients), more than 35 percent do not receive treatment because of cost-related issues, and approximately 20 percent do not receive treatment because of payer restrictions.

The new Strategic Insights report entitled Trends in Reimbursement for Immune Biologics: Strategies for Success also finds that in an attempt to control the increasing costs associated with biologics/novel oral agents, particularly the non-TNF-alpha inhibitors, payers frequently use a wide range of strategies and tactics such as prior authorization, step-therapy requirements and blocking copay assistance programs for nonpreferred agents.

"As new biologics/novel oral agents and biosimilars enter the RA and psoriasis markets, drug marketers can expect more payer scrutiny and restrictions," said Decision Resources Analyst Adi Reske, Ph.D. "Payers will demand extensive data and greater discounts and rebates to justify giving a therapy preferred coverage. To overcome the increasing barriers, drug marketers must employ different strategies including more cost-effective agents, head-to-head clinical data, and greater discounts and rebates."

About Strategic Insights
Strategic Insights is a new series of high-
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
2. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
3. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
6. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
7. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
8. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
9. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
10. Global Spinal Devices and Biologics Market 2011-2015
11. Synthetic Biologics Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ANDOVER, Massachusetts y LONDRES, August 29, 2015 ... Inteligencia Anatómica para los sistemas ... reproducibles en Ecografía, tiempos de examen rápidos ... se traduce en mayor confianza diagnóstica en el proceso ... Philips  (NYSE: PHG, AEX: PHIA) ha anunciado hoy el ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Pranoprofen Market, ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation ... an inflammatory drug, pranoprofen was later developed into ... the trade name of pranopulin for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson ... Inc. (Nasdaq: PDCO ), is now an ... announced acquisition of Patterson Medical by Madison Dearborn ... retain its name for a transition period before ... rehabilitation and sports medicine products.  With the focused ...
Breaking Medicine Technology:Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Investigation Report on China's Pranoprofen Market, 2010-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... April 3, 2011 Regado Biosciences, Inc., a privately ... active control agents, announced today the primary results of ... lead product, the anticoagulation system REG1, at the i2 ... Annual Scientific Session & Expo in New Orleans, LA. ...
... of the SPIRIT II, III, IV and COMPARE trials presented ... ABT ) market-leading XIENCE V ® Everolimus ... all four trials, two-year results on the safety and efficacy ... and TAXUS ® Express2™ Paclitaxel-Eluting Coronary Stent Systems ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 2Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 3Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V® 4
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ... of global cosmeceutical and skin care brands. Mr. Fernandez comes with a ... years working in operations, purchasing and management for some of the nations biggest ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at ... Community Colleges , will be hosting a Job Expo to provide a professional, open ... The Expo has expanded to much more than just a typical job and career ...
(Date:8/29/2015)... PA (PRWEB) , ... August 29, 2015 , ... ... due to insufficient scrotal support and protection against dribbled urine and sweat. "In ... from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides ...
(Date:8/29/2015)... NY (PRWEB) , ... August 29, 2015 , ... Next ... end of summer (which astronomically, officially ends on September 22nd this year). For IT ... cyber security hangovers linger on which could prove far more costly than a simple ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... The popular ... James Earl Jones, recently announced that it will be devoting an entire short segment ... affecting millions of people around the globe on a daily basis, but recent advancements ...
Breaking Medicine News(10 mins):Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Ill., Jan. 30 SpineMark Corporation,a spinal care ... develop Spine Centers of Excellence, has entered into ... spinal care at,cost effective rates through the first ... the Healthplace Surgery Benefit(TM). As a result,of ...
... Snyder, president of Catholic Charities USA, issued the ... the State Children,s Health Insurance Program (SCHIP), a ... that do not qualify for Medicaid. The House ... on a compromise version of the legislation, which ...
... Jan. 30 Wellesse, manufacturers of new Liquid ... challenges participants to assess their vitamin knowledge for ... a personal nutrition consultation and a year,s supply ... research on Vitamin D dominates the headlines lately, ...
... for menopausal symptoms, FDA says , , FRIDAY, Jan. ... hormones or "bio-identical hormone replacement therapy," and they ... lose weight to preventing senility. , They,re touted ... conventional hormone-replacement therapy. , But the U.S. Food ...
... Co., Inc. (NYSE Alternext: TPI), a manufacturer and ... Chengdu, China,today announced that the Company has begun ... stock repurchase program. These shares will be,retired to ... shares of its,common stock. , ...
... exclusivity on the 500 mg strengthPITTSBURGH, Jan. 30 ... that its subsidiary Mylan Pharmaceuticals Inc. has received final ... for its Abbreviated New Drug Application (ANDA) for Divalproex ... mg. Mylan has been awarded 180 days of marketing ...
Cached Medicine News:Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Catholic Charities USA Praises Congress for Protecting Health Care for Low-income Children 2Health News:Test Your Vitamin D Knowledge: Wellesse Liquid Sunshine Instant Win and Sweepstakes 2Health News:The Truth About 'Bio-identical' Hormone Therapy 2Health News:The Truth About 'Bio-identical' Hormone Therapy 3Health News:The Truth About 'Bio-identical' Hormone Therapy 4Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: